| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| is apixaban a generic for eliquis | 0.78 | 0.5 | 7187 | 17 |
| is apixaban the generic name for eliquis | 1.02 | 1 | 4517 | 47 |
| eliquis generic apixaban availability | 1.67 | 0.7 | 745 | 12 |
| is apixaban a generic drug for eliquis | 1.17 | 0.3 | 3222 | 53 |
| is apixaban the same as eliquis | 1.79 | 0.4 | 9230 | 35 |
| is eliquis and apixaban the same drug | 0.36 | 0.1 | 3937 | 70 |
| is apixaban and eliquis the same thing | 1.6 | 1 | 9225 | 83 |
| are apixaban and eliquis the same | 1.38 | 0.4 | 3413 | 37 |
| what is apixaban eliquis | 1.97 | 1 | 1959 | 21 |
| are eliquis and apixaban the same thing | 1.7 | 0.3 | 5135 | 98 |
| apixaban eliquis drug classification | 1.98 | 1 | 7522 | 93 |
| apixaban eliquis drug class | 0.43 | 0.1 | 5679 | 55 |
| eliquis apixaban 2 5 mg | 0.83 | 0.8 | 3353 | 46 |
| eliquis apixaban 5 mg | 1.01 | 0.2 | 3368 | 7 |
Generic name: apixaban (a PIX a ban) Brand name: Eliquis, Eliquis Starter Pack for Treatment of DVT and PE Dosage forms: oral tablet (2.5 mg; 5 mg) Drug class: Factor Xa inhibitors Medically reviewed by Drugs.com on Jun 11, 2021. Written by Cerner Multum.
Is Eliquis a generic?The FDA (U.S. Food and Drug Administration) has approved the first Eliquis generic, apixaban, which will be a lower-cost blood thinner alternative. Generic Eliquis will be much more affordable than the brand-name drug once it’s available for sale.
What is Eliquis (apixaban)?Eliquis is a brand name of apixaban, approved by the FDA in the following formulation (s): ELIQUIS (apixaban - tablet;oral) Manufacturer: BRISTOL MYERS SQUIBB Approval date: December 28, 2012
What is the strength of apixaban?apixaban tablet;oral. Manufacturer: ACCORD HLTHCARE Approval date: July 28, 2020 Strength(s): 2.5MG , 5MG ; Manufacturer: INDOCO Approval date: September 11, 2020 Strength(s): 2.5MG , 5MG ; Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eliquis. These medications may be counterfeit and potentially unsafe.
